MA32095B1 - Inhibiteurs d'aldh-2 dans le traitement d'une accoutumance - Google Patents

Inhibiteurs d'aldh-2 dans le traitement d'une accoutumance

Info

Publication number
MA32095B1
MA32095B1 MA33106A MA33106A MA32095B1 MA 32095 B1 MA32095 B1 MA 32095B1 MA 33106 A MA33106 A MA 33106A MA 33106 A MA33106 A MA 33106A MA 32095 B1 MA32095 B1 MA 32095B1
Authority
MA
Morocco
Prior art keywords
aldh
addiction
inhibitors
treatment
amphetamines
Prior art date
Application number
MA33106A
Other languages
Arabic (ar)
English (en)
Inventor
Yaroslav Bilokin
Elfatih Elzein
Jeff Zablocki
Michael Organ
Thao Perry
Tetsuya Kobayashi
Matthew Abelman
Rao Kalla
Peidong Fan
Ivan Diamond
Robert Jiang
Maria Pia Arolfo
Xiaofen Li
Lina Yao
Zhan Jiang
Wing Ming Keung
Guoxin Tao
Original Assignee
Endowment For Res In Human Biology Inc
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endowment For Res In Human Biology Inc, Gilead Palo Alto Inc filed Critical Endowment For Res In Human Biology Inc
Publication of MA32095B1 publication Critical patent/MA32095B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La présente invention concerne de nouveaux dérivés d'isoflavone, dont la structure est représentée par la formule (i), qui se révèlent utiles en tant qu'inhibiteurs d'aldh-2 pour traiter des mammifères qui dépendent de substances créant un effet d'accoutumance, par exemple l'accoutumance à un agent produisant de la dopamine tel que la cocaïne, la morphine, les amphétamines, la nicotine et l'alcool.
MA33106A 2008-01-24 2010-08-23 Inhibiteurs d'aldh-2 dans le traitement d'une accoutumance MA32095B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/051862 WO2009094028A1 (fr) 2008-01-24 2008-01-24 Inhibiteurs d'aldh-2 dans le traitement d'une accoutumance

Publications (1)

Publication Number Publication Date
MA32095B1 true MA32095B1 (fr) 2011-02-01

Family

ID=39731733

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33106A MA32095B1 (fr) 2008-01-24 2010-08-23 Inhibiteurs d'aldh-2 dans le traitement d'une accoutumance

Country Status (13)

Country Link
EP (1) EP2254878A1 (fr)
JP (1) JP2011510072A (fr)
KR (1) KR20100130589A (fr)
CN (1) CN101925590A (fr)
AU (1) AU2008348372A1 (fr)
BR (1) BRPI0822129A2 (fr)
CA (1) CA2712750A1 (fr)
EC (1) ECSP10010417A (fr)
IL (1) IL207127A0 (fr)
MA (1) MA32095B1 (fr)
MX (1) MX2010008111A (fr)
WO (1) WO2009094028A1 (fr)
ZA (1) ZA201004671B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102161648A (zh) * 2011-02-18 2011-08-24 中国药科大学 具有选择性雌激素受体调节活性的异黄酮类化合物的制备方法及其用途
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
AR087700A1 (es) 2011-08-30 2014-04-09 Gilead Sciences Inc Inhibidores de aldh-2 en el tratamiento de adicciones
CA3077606A1 (fr) * 2017-10-16 2019-04-25 Amygdala Neurosciences, Inc. Polytherapie pour la prevention d'une addiction
CN108276374B (zh) * 2018-03-29 2020-01-31 天津科技大学 黄酮类芳香化酶抑制剂及其制备方法与应用
CN110922394B (zh) * 2019-11-21 2021-04-06 中国科学院宁波材料技术与工程研究所 一种基于天然黄酮类化合物的生物基本征阻燃环氧树脂前驱体及其制备方法和应用
WO2023235753A2 (fr) * 2022-05-31 2023-12-07 University Of Maryland, Baltimore Inhibiteurs d'aldh2 et leurs procédés d'utilisation
WO2023244584A1 (fr) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Composés inhibiteurs d'aldh-2 et procédés d'utilisation
US20230399299A1 (en) 2022-06-14 2023-12-14 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU162377B (fr) * 1970-05-27 1973-02-28
US4166862A (en) * 1971-05-25 1979-09-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Animal feed containing anabolic isoflavones
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
AU3899199A (en) * 1998-05-12 1999-11-29 Endowment for Research in Human Biology, Inc., The Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
EP1524974A4 (fr) * 2001-05-04 2007-12-05 Paratek Pharm Innc Composes modulateurs de facteurs de transcription et procedes d'utilisation
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
MXPA05000122A (es) * 2002-06-27 2005-12-14 Endowment For Res In Human Bio Compuestos utiles para la inhibicion de aldehido-deshidrogenasa.
CA2571421A1 (fr) * 2004-06-24 2006-01-05 Nicholas Valiante Composes utilises pour l'immunopotentialisation
PL377180A1 (pl) * 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
US20080032995A1 (en) * 2006-07-27 2008-02-07 Jeff Zablocki Aldh-2 inhibitors in the treatment of drug addiction
WO2009061924A2 (fr) * 2007-11-06 2009-05-14 Cv Therapeutics, Inc. Inhibiteurs aldh-2 dans le traitement de troubles psychiatriques

Also Published As

Publication number Publication date
CA2712750A1 (fr) 2009-07-30
AU2008348372A1 (en) 2009-07-30
JP2011510072A (ja) 2011-03-31
ECSP10010417A (es) 2010-11-30
BRPI0822129A2 (pt) 2015-06-23
MX2010008111A (es) 2010-11-30
IL207127A0 (en) 2010-12-30
EP2254878A1 (fr) 2010-12-01
ZA201004671B (en) 2011-03-30
WO2009094028A1 (fr) 2009-07-30
CN101925590A (zh) 2010-12-22
KR20100130589A (ko) 2010-12-13

Similar Documents

Publication Publication Date Title
MA32095B1 (fr) Inhibiteurs d'aldh-2 dans le traitement d'une accoutumance
MA30434B1 (fr) Inhibiteurs d'aldh-2 utilises pour le traitement d'une accoutumance
MA35404B1 (fr) Composés pour le traitement de la toxicomanie
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA30228B1 (fr) Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4
MA28077A1 (fr) Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA33737B1 (fr) Dérivés de glycoside et utilisations de ceux-ci
MA30394B1 (fr) Synthese d'acylaminoalcenylene-amides pouvant etre employes en tant qu'antagonistes de la substance p
MA33072B1 (fr) Composes pyridazinone
MA32171B1 (fr) Compose heterocyclique
MA32903B1 (fr) Inhibiteurs de proteine-kinases
MA38170B1 (fr) Nouveaux acides indanyloxydihydrobenzofuranylacétiques
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA30262B1 (fr) Pesticides contenant une structure bis (amide) bicyclique.
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA30762B1 (fr) Anticorps specifiques du prlr et leurs utilisations
MA30607B1 (fr) N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d'antagonistes du recepteur p2x7 et procedes d'utilisation
AR069752A1 (es) Composiciones que comprenden agonistas nicotinicos y su uso y kit